| Name | Title | Contact Details |
|---|
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
Kleo Pharmaceuticals is advancing the field of immunotherapy by developing small molecules that emulate biologics.
Roha Food Colors is a Trumbull, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
itsRX is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CRC Consulting is a Roslindale, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.